Literature DB >> 32919410

Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications.

Alessio Squassina1, Mirko Manchia2,3,4, Claudia Pisanu5, Raffaella Ardau6, Carlo Arzedi2,3, Alberto Bocchetta5,6, Paola Caria7, Cristina Cocco8, Donatella Congiu5, Eleonora Cossu2,3, Tinuccia Dettori7, Daniela Virginia Frau7, Mario Garzilli2,3, Elias Manca8, Anna Meloni5, Maria Antonietta Montis2,3, Andrea Mura2,3, Mariella Nieddu7, Barbara Noli8, Pasquale Paribello2,3, Federica Pinna2,3, Renato Robledo7, Giovanni Severino5, Valeria Sogos9, Maria Del Zompo5,6, Gian Luca Ferri8, Caterina Chillotti6, Roberta Vanni7, Bernardo Carpiniello2,3.   

Abstract

Individuals with severe psychiatric disorders have a reduced life expectancy compared to the general population. At the biological level, patients with these disorders present features that suggest the involvement of accelerated aging, such as increased circulating inflammatory markers and shorter telomere length (TL). To date, the role of the interplay between inflammation and telomere dynamics in the pathophysiology of severe psychiatric disorders has been scarcely investigated. In this study we measured T-lymphocytes TL with quantitative fluorescent in situ hybridization (Q-FISH) and plasma levels of inflammatory markers in a cohort comprised of 40 patients with bipolar disorder (BD), 41 with schizophrenia (SZ), 37 with major depressive disorder (MDD), and 36 non-psychiatric controls (NPC). TL was shorter in SZ and in MDD compared to NPC, while it was longer in BD (model F6, 137 = 20.128, p = 8.73 × 10-17, effect of diagnosis, F3 = 31.870; p = 1.08 × 10-15). There was no effect of the different classes of psychotropic medications, while duration of treatment with mood stabilizers was associated with longer TL (Partial correlation controlled for age and BMI: correlation coefficient = 0.451; p = 0.001). Levels of high-sensitivity C-Reactive Protein (hsCRP) were higher in SZ compared to NPC (adjusted p = 0.027), and inversely correlated with TL in the whole sample (r = -0.180; p = 0.042). Compared to NPC, patients with treatment resistant (TR) SZ had shorter TL (p = 0.001), while patients with TR MDD had higher levels of tumor necrosis factor-α (TNFα) compared to NPC (p = 0.028) and to non-TR (p = 0.039). Comorbidity with cardio-metabolic disorders did not influence the observed differences in TL, hsCRP, and TNFα among the diagnostic groups. Our study suggests that patients with severe psychiatric disorders present reduced TL and increased inflammation.

Entities:  

Year:  2020        PMID: 32919410      PMCID: PMC7784910          DOI: 10.1038/s41386-020-00844-z

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  85 in total

Review 1.  Estimating the true global burden of mental illness.

Authors:  Daniel Vigo; Graham Thornicroft; Rifat Atun
Journal:  Lancet Psychiatry       Date:  2016-02       Impact factor: 27.083

2.  Severe mental illness and risk of cardiovascular disease.

Authors:  John W Newcomer; Charles H Hennekens
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

Review 3.  Bipolar disorders.

Authors:  Eduard Vieta; Michael Berk; Thomas G Schulze; André F Carvalho; Trisha Suppes; Joseph R Calabrese; Keming Gao; Kamilla W Miskowiak; Iria Grande
Journal:  Nat Rev Dis Primers       Date:  2018-03-08       Impact factor: 52.329

Review 4.  The epidemiology of excess mortality in people with mental illness.

Authors:  David Lawrence; Stephen Kisely; Joanne Pais
Journal:  Can J Psychiatry       Date:  2010-12       Impact factor: 4.356

Review 5.  Premature mortality from general medical illnesses among persons with bipolar disorder: a review.

Authors:  Babak Roshanaei-Moghaddam; Wayne Katon
Journal:  Psychiatr Serv       Date:  2009-02       Impact factor: 3.084

6.  Risks of all-cause and suicide mortality in mental disorders: a meta-review.

Authors:  Edward Chesney; Guy M Goodwin; Seena Fazel
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

7.  Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC).

Authors:  M De Hert; J M Dekker; D Wood; K G Kahl; R I G Holt; H-J Möller
Journal:  Eur Psychiatry       Date:  2009-08-13       Impact factor: 5.361

8.  Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.

Authors:  Nancy H Liu; Gail L Daumit; Tarun Dua; Ralph Aquila; Fiona Charlson; Pim Cuijpers; Benjamin Druss; Kenn Dudek; Melvyn Freeman; Chiyo Fujii; Wolfgang Gaebel; Ulrich Hegerl; Itzhak Levav; Thomas Munk Laursen; Hong Ma; Mario Maj; Maria Elena Medina-Mora; Merete Nordentoft; Dorairaj Prabhakaran; Karen Pratt; Martin Prince; Thara Rangaswamy; David Shiers; Ezra Susser; Graham Thornicroft; Kristian Wahlbeck; Abe Fekadu Wassie; Harvey Whiteford; Shekhar Saxena
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

9.  Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.

Authors:  Merete Nordentoft; Kristian Wahlbeck; Jonas Hällgren; Jeanette Westman; Urban Osby; Hassan Alinaghizadeh; Mika Gissler; Thomas Munk Laursen
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

Review 10.  Schizophrenia.

Authors:  Michael J Owen; Akira Sawa; Preben B Mortensen
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321

View more
  6 in total

1.  Leukocyte telomere length in patients with schizophrenia and related disorders: a meta-analysis of case-control studies.

Authors:  Miriam Ayora; David Fraguas; Renzo Abregú-Crespo; Sandra Recio; María A Blasco; Ana Moises; Aksinya Derevyanko; Celso Arango; Covadonga M Díaz-Caneja
Journal:  Mol Psychiatry       Date:  2022-04-07       Impact factor: 15.992

2.  Mental Disorders Are Associated With Leukocytes Telomere Shortening Among People Who Inject Drugs.

Authors:  Mélusine Durand; Nicolas Nagot; Laurent Michel; Sao Mai Le; Huong Thi Duong; Roselyne Vallo; Amélie Vizeneux; Delphine Rapoud; Hoang Thi Giang; Catherine Quillet; Nham Thi Tuyet Thanh; Khuat Thi Hai Oanh; Vu Hai Vinh; Jonathan Feelemyer; Philippe Vande Perre; Khue Pham Minh; Didier Laureillard; Don Des Jarlais; Jean-Pierre Molès
Journal:  Front Psychiatry       Date:  2022-06-17       Impact factor: 5.435

3.  Circular RNA CircCOL5A1 Sponges the MiR-7-5p/Epac1 Axis to Promote the Progression of Keloids Through Regulating PI3K/Akt Signaling Pathway.

Authors:  Wenchang Lv; Shengxuan Liu; Qi Zhang; Weijie Hu; Yiping Wu; Yuping Ren
Journal:  Front Cell Dev Biol       Date:  2021-01-21

4.  Epigenetic clocks in relapse after a first episode of schizophrenia.

Authors:  Àlex-González Segura; Llucia Prohens; Gisela Mezquida; Silvia Amoretti; Miquel Bioque; María Ribeiro; Xaquin Gurriarán-Bas; Lide Rementería; Daniel Berge; Roberto Rodriguez-Jimenez; Alexandra Roldán; Edith Pomarol-Clotet; Angela Ibáñez; Judith Usall; Maria Paz García-Portilla; Manuel J Cuesta; Mara Parellada; Ana González-Pinto; Esther Berrocoso; Miquel Bernardo; Sergi Mas
Journal:  Schizophrenia (Heidelb)       Date:  2022-07-22

5.  Analysis on in vitro effect of lithium on telomere length in lymphoblastoid cell lines from bipolar disorder patients with different clinical response to long-term lithium treatment.

Authors:  Alessio Squassina; Anna Meloni; Donatella Congiu; Panagiotis Bosganas; George P Patrinos; Rixing Lin; Gustavo Turecki; Giovanni Severino; Raffaella Ardau; Caterina Chillotti; Claudia Pisanu
Journal:  Hum Genomics       Date:  2022-10-17       Impact factor: 6.481

Review 6.  Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

Authors:  Elias Manca
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-11       Impact factor: 10.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.